Biopharmaceutical company
Appears in 1 story · Last updated Oct 29, 2026
Original developer of tivunatamig; retains China rights while Pfizer runs the global program
At the 2026 European Society for Medical Oncology congress, 3SBio reported a median progression-free survival (the time patients live without the disease worsening) of 13.6 months in squamous and 13.8 months in non-squamous advanced lung cancer. The drug, tivunatamig, was combined with chemotherapy, and the control groups received tislelizumab plus chemotherapy, reaching 8.3 and 9.7 months.
Updated Oct 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
